



Liver News Elsewhere

Protective effects of serum bilirubin on peripheral vascular disease

Libor Vitek;¹ Harvey A. Schwertner²

Abstract

Background: Bilirubin, with recently recognized anti-oxidant and anti-inflammatory activity, has emerged as a candidate for atheroprotection. We hypothesized that higher levels of bilirubin would reduce susceptibility to peripheral arterial disease (PAD). **Methods and results:** We analyzed 7,075 adults with data available on the ankle brachial index, serum total bilirubin level, and PAD risk factors in the National Health and Nutrition Examination Survey (1999 to 2004), a nationally representative cross-sectional examination of the United States population. A 0.1 mg/dL increase in bilirubin level was associated with a 6% reduction in the odds of PAD (OR 0.94 [95% CI 0.90 to 0.98]) after adjustment for age, gender, race/ethnicity, smoking status, diabetes, hypertension, hypercholesterolemia, chronic kidney disease, CRP, and homocysteine. This result was not dependent on bilirubin levels above the reference range, liver disease, or alcohol intake. The inverse association of bilirubin with PAD tended to be stronger among men (OR 0.90 [95% CI 0.85 to 0.96]) compared with women (OR 0.97 [95% CI 0.91 to 1.04]; *P* (interaction) = 0.05), and was stronger among active smokers

(OR 0.81 [95% CI 0.73 to 0.90]) compared with non-smokers (OR 0.97 [95% CI 0.93 to 1.02]; *P* (interaction) < 0.01). **Conclusions:** Increased serum total bilirubin level is associated with reduced PAD prevalence. This result is consistent with the hypothesis that bilirubin is protective from PAD.

Key words: Bilirubin, antioxidant, atherosclerosis, peripheral artery disease.

Abstract published under permission of the Lippincott-Raven Publishers, Williams & Wilkins

Comment

Serum bilirubin, a potent endogenous antioxidant, has been linked to a number of oxidative stress-mediated diseases including atherosclerosis, cancer, certain rheumatological as well as to neurodegenerative diseases.¹ Additional evidence supporting the inverse association of bilirubin and atherosclerosis has been recently reported by Drs. Perlstein *et al.*² In that study, they retrospectively studied the relationship between serum bilirubin levels and peripheral artery disease (PAD) in more than 7,000 adults from the National Health and Nutrition Examination Survey (NHANES). After adjustment for possible confounding factors, each 0.1 mg/dL increase in serum bilirubin level was found to be associated with 6% reduction in the odds of having PAD. This association was even stronger in men (OR 0.90 [95% CI 0.85-0.96]) and active smokers (OR 0.81 [95% CI 0.73-0.90]).

Results of this, so far the largest study of bilirubin and PAD, extends the evidence that bilirubin is a marker for atherosclerosis. The data provided are consistent with other (not discussed) reports showing that increased serum bilirubin levels are associated with a reduced prevalence of PAD.³⁻¹¹ Although Perlstein and colleagues in their paper warn of possible U-shape relationship between serum bilirubin and PAD, this warning is based largely on two previous reports^{12,13} in which improper¹² or no¹³ adjustment for underlying liver disease was performed. When proper adjustment for elevated liver function tests in Breimer *et al.*'s study¹² was performed, the U-shape relationship disappeared.¹⁴ Moreover, several more recent studies have demonstrated that mildly elevated se-

¹ 4th Department of Internal Medicine and Institute of Clinical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, Czech Republic.

² Clinical Research, Wilford Hall Medical Center, San Antonio, Texas, USA.

Article commented:

Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. *Arterioscler Thromb Vasc Biol* 2008; 28: 166-72.

Address for correspondence:

Libor Vitek, M.D., PhD, MBA
Associate Professor of Medical Chemistry and Biochemistry
4th Department of Internal Medicine and
Institute of Clinical Biochemistry and Laboratory Diagnostics
1st Medical Faculty
Charles University of Prague U Nemocnice 2
Prague 2, 12808 Czech Republic
E-mail: vitek@cesnet.cz

rum unconjugated bilirubin levels protects from both coronary¹⁵ and peripheral atherosclerotic disease.^{8,10} It should be also noted that elevated aminotransferase activity, a surrogate marker of liver damage, occurs in about 10% of the US population,¹⁶ and is directly related to CHD risk.¹⁷⁻¹⁹ As a result, elevated aminotransferase activity could be concealing the protective effects of mild isolated hyperbilirubinemia. In this respect it is important to note that the protective effects of bilirubin on PAD in the Perlstein *et al.*'s study were detected in both individuals with supraphysiological bilirubin concentrations as well as in subsets of individuals that did not have underlying liver disease.²

Therefore, it appears likely that additional large well-designed prospective studies that adjust for all possible confounding factors including liver disease will establish that higher levels of serum bilirubin are indeed protective.

Supported by a grant No. MSM 0021620807 given by the Czech Ministry of Education.

References

1. Vitek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. *Adv Clin Chem* 2007; 43: 1-57.
2. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. *Arterioscler Thromb Vasc Biol* 2008; 28: 166-72.
3. Breimer LH, Spyropolous KA, Winder AF, Mikhailidis DP, Hamilton G. Is bilirubin protective against coronary artery disease? *Clin Chem* 1994; 40: 1987-8.
4. Nicholl P, Mikhailidis D, Hamilton G, Spyropolous LK, Winder AF. Bilirubin and peripheral vascular disease. *Br J Surg* 1995; 82: 1561-2.
5. Kangas E, Teittinen K, Vilkkio P, Utriainen S. Bilirubin and peripheral vascular disease. *Br J Surg* 1999; 86: 713.
6. Krijgsman B, Mikhailides DP, Winder AF, Hamilton G. Bilirubin and peripheral vascular disease [letter]. *Br J Surg* 2000; 87: 251-2.
7. Cerne D, Ledinski G, Kager G, Greilberger J, Wang XS, Jurgens G. Comparison of laboratory parameters as risk factors for the presence and the extent of coronary or carotid atherosclerosis: the significance of apolipoprotein B to apolipoprotein all ratio. *Clin Chem Lab Med* 2000; 38: 529-38.
8. Ishizaka N, Ishizaka Y, Takahashi E, Yamakado M, Hashimoto H. High serum bilirubin level is inversely associated with the presence of carotid plaque. *Stroke* 2001; 32: 580-3.
9. Krijgsman B, Papadakis JA, Ganotakis ES, Mikhailidis DP, Hamilton G. The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. *Int Angiol* 2002; 21: 44-52.
10. Vitek L, Novotný L, Šperl M, Holaj R, Spáčil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. *Cerebrovasc Dis* 2006; 21: 408-14.
11. Yilmaz FM, Akay H, Duranay M, Yilmaz G, Oztekin PS, Koşar U, et al. Carotid atherosclerosis and cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. *Clin Biochem* 2007; 40: 1361-6.
12. Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. *Clin Chem* 1995; 41: 1504-8.
13. Troughton JA, Woodside JV, Young IS, et al. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). *Eur J Cardiovasc Prev Rehabil* 2007; 14: 79-84.
14. Novotný L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: A meta-analysis of published studies. *Exp Biol Med* 2003; 228: 568-71.
15. Vitek L, Jirsa Jr. M, Brodanová M, Kaláb M, Mareček Z, Danzig V, Novotný L, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. *Atherosclerosis* 2002; 160: 449-56.
16. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. *Am J Gastroenterol* 2006; 101: 76-82.
17. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. *Diabetes Metab Res Rev* 2006; 22: 437-43.
18. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, Diamant M. Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study. *Atherosclerosis* 2007; 191: 391-6.
19. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. *Hepatology* 2006; 43: 1145-51.